Nuvectis Pharma, Inc. · NASDAQ:NVCT

Nuvectis Pharma — Investor Presentation (March 2023)

23 slides from Nuvectis Pharma's investor presentation, March 2023

  1. Slide 1: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2023 (NASDAQ: NVCT)

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Nuvectis Pharma, Inc. Certain statements in this presentation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Statements other than those of his

  3. Slide 3: Nuvectis Pharma – Key Highlights

    Nuvectis Pharma – Key Highlights Our Approach to  Select novel, rationally-designed drug candidates for serious conditions of unmet need in oncology Precision Medicine  A focused clinical/regulatory strategy  Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma NXP800 

  4. Slide 4: Management Team

    Management Team Track record of success Jelmyto® (mitomycin) Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer NuvectisPharma, Inc. 4

  5. Slide 5: Nuvectis Precision Medicine Pipeline

    Nuvectis Precision Medicine Pipeline Drug Discovery and Lead Indication Optimization IND-Enabling Phase 1a Phase 1b Phase 2 Phase 3 Candidate  ARID1a-mutated ovarian cancer Phase 1b in ARID1a-mutated ovarian cancer pending commencement in NXP800 • clear cell carcinoma collaboration with ENGOT and G

  6. Slide 6: About NXP800

    4 About NXP800

  7. Slide 7: NXP800 Key Highlights

    NXP800 Key Highlights Precision Medicine  HSF1 pathway inhibitor discovered and optimized at the Institute of Cancer Research (ICR) in the UK Approach  Substantial efficacy in ARID1a-mutated xenograft models Focused Clinical &  Fast Track Designation granted for the treatment of platinum resistan

  8. Slide 8: Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin)

    Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts (NXP800 vs. Cisplatin) Preclinical proof of concept leading to selection of initial target indications SKOV-3 Model TOV-21G Model NuvectisPharma, Inc. 8

  9. Slide 9: ARID1a Mutations – Opportunities in Additional Solid Tumors

    ARID1a Mutations – Opportunities in Additional Solid Tumors Est. # of Patients Indication Est. Incidence • ARID1A is a prevalent genetic mutation that can w/ ARID1a protein (% patients w/ARID-1a mutation) (US)* loss (US) be tested using commercially available assays to identify patients for studies

  10. Slide 10: Substantial Antitumor Activity in Additional ARID1a-Mutated Solid Tumors

    Substantial Antitumor Activity in Additional ARID1a- Mutated Solid Tumors Additional potential development opportunities SNU-1 Model (Gastric Carcinoma) NuvectisPharma, Inc. 10

  11. Slide 11: About NXP900

    4 About NXP900

  12. Slide 12: NXP900 Key Highlights

    NXP900 Key Highlights  Discovered at the University of Edinburgh, Scotland Precision Medicine Approach  A potent, novel, small molecule inhibitor of YES1/SRC signaling  Highly selective Differentiated  Unique mechanismm of action Features  Lack of immunosuppression  Ability to cross the blood-

  13. Slide 13: Structure of SRC Family Kinases (SFK)

    Structure of SRC Family Kinases (SFK) Scaffold Domain SH2 and SH3 domains of SRC kinase family members constitute a scaffold to which other pro-oncogenic signaling molecules are recruited inducing pro-oncogenic signals Catalytic Domain SRC kinase family members (such as Src and Yes1) transmit pro-on

  14. Slide 14: NXP900 Completely Shuts Down Signaling of SFK

    NXP900 Completely Shuts Down Signaling of SFK Differentiated vs. other multi-kinase inhibitors that only achieve a partial SRC pathway shut down NXP900: Complete shutdown of Other multi-kinase inhibitors: Partial No inhibitor: Fully active SRC the SRC pathway shutdown of the SRC pathway NON- FNCTION

  15. Slide 15: NXP900 Kinome Profiling Demonstrates High Selectivity

    NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 15

  16. Slide 16: Targeting YES1 in Cancers of Squamous Cell Origin

    Targeting YES1 in Cancers of Squamous Cell Origin  YES1 gene amplification drives tumor growth via activating phosphorylation of YAP1.  YES1 gene amplification is prevalent in cancers of squamous cell origin.  Genetic mutation in FAT1 and other alterations along the Hippo pathway are common in ca

  17. Slide 17: Preclinical Proof of Concept

    Preclinical Proof  Squamous Cell Cancers of Concept  Group 4 Medulloblastoma  Potential Combination Strategies NuvectisPharma, Inc. 17

  18. Slide 18: Squamous Cell Cancers

    Squamous Cell Cancers NXP900 demonstrated robust antitumor activity in xenograft models of squamous cell cancers * YES1 gene amplification is a known genetic alteration in KYSE70 cells * Heterozygous FAT1 copy loss is a known genetic alteration in Cal27 cells NuvectisPharma, Inc. 18

  19. Slide 19: Group 4 Medulloblastoma

    Group 4 Medulloblastoma SRC signaling is a hallmark of Group 4 medulloblastoma a Treatment Window Presented June 12th, 2022 at SIOPE Brain Tumor Group in Hamburg, Germany, by the Pediatric Solid Tumor Biology and Therapeutics Team (led by Prof. Louis Chesler of The Institute of Cancer Research in Lo

  20. Slide 20: Potential Combination Strategies

    Potential Combination Strategies SRC (in NSCLC) and YES1 (in mCRPC) are implicated in development of resistance to osimerinib (Tagrisso) and enzalutamide (Xtandi) NXP900 in combination with enzalutamide overcomes NXP900 in combination with osimertinib overcomes resistance in vitro resistance in vivo

  21. Slide 21: Financial and NVCT Stock Highlights

    Financial and NVCT Stock Highlights  Cash position • $23.6M at the end of 3Q2022 • Runway into H2 2024  IPO in February 2022 at $5 per share • 3 Co-founders own approximately 35%  Covering analysts • HC Wainwright & Co – Joe Pantginis • Roth Capital Partners – Jonathan Aschoff • Ladenburg Thalman

  22. Slide 22: Nuvectis Investment Highlights

    Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology  Initiation of the NXP800 Phase 1b in ARID1a-mutated ovarian cancers Significant Milestones  IND/equivalent submission for NXP900 followed by commencement of the Phase 1 program Expe

  23. Slide 23: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology March 2023 (NASDAQ: NVCT)

Nuvectis Pharma — Investor Presentation (March 2023) on 6ix